Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7613210 | 0.88 | CYP17A1 (0.50) | CYP17A1PSMB8NAMPTPTPN11PPARG | |
| SCHEMBL1855586 | 0.86 | CYP17A1 (0.49) | CYP17A1PSMB8NAMPTPTPN11PPARG | |
| SCHEMBL13055402 | 0.83 | CYP17A1 (0.59) | CYP17A1PSMB8NAMPTPTPN11CA12 | |
| SCHEMBL11987756 | 0.82 | CYP17A1 (0.46) | CYP17A1PSMB8NAMPTPTPN11PPARG | |
| SCHEMBL24263030 | 0.82 | CYP17A1 (0.50) | CYP17A1PSMB8NAMPTPTPN11PPARG | |
| SCHEMBL104556 | 0.82 | RAB9A (0.55) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL4993885 | 0.81 | CYP17A1 (0.46) | CYP17A1PSMB8NAMPTPTPN11PPARG | |
| SCHEMBL27284560 | 0.81 | CYP17A1 (0.49) | CYP17A1PSMB8NAMPTPTPN11PPARG | |
| SCHEMBL27284495 | 0.81 | CYP17A1 (0.49) | CYP17A1PSMB8NAMPTPTPN11PPARG | |
| SCHEMBL1856703 | 0.80 | CYP17A1 (0.45) | CYP17A1PSMB8NAMPTPTPN11PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4100393-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-9296726-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-29 | — | — | US | disclosed |
| US-9296726-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-29 | — | — | US | disclosed |
| US-9296726-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-29 | — | — | US | disclosed |
| US-20150051196-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051196-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | US | disclosed |
| US-20080275031-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | ILLIG CARL R | 2008-11-06 | — | — | US | disclosed |
| US-20080275031-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | ILLIG CARL R | 2008-11-06 | — | — | US | disclosed |
| US-7414050-B2 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| US-7414050-B2 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| US-7414050-B2 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| WO-2007124316-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124316-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | CYP17A1 3048/4885PSMB8 4185/4885NAMPT 1/4885 |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | MUSK, CHUK, PNCK | CYP17A1 2939/4885PSMB8 2164/4885NAMPT 2672/4885 |
| US-20150051196-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CYP17A1 2766/4885PSMB8 3325/4885NAMPT 2897/4885 |
| US-20080275031-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | MUSK, CHUK, CAMK4 | CYP17A1 2888/4885PSMB8 2366/4885NAMPT 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.